Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Curocell Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩33,050.00 |
52 Week High | ₩43,000.00 |
52 Week Low | ₩18,200.00 |
Beta | 0 |
1 Month Change | 1.23% |
3 Month Change | 4.92% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 52.30% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
A372320 | KR Biotechs | KR Market | |
---|---|---|---|
7D | 4.4% | -0.7% | -0.5% |
1Y | n/a | 2.4% | 5.0% |
Return vs Industry: Insufficient data to determine how A372320 performed against the KR Biotechs industry.
Return vs Market: Insufficient data to determine how A372320 performed against the KR Market.
Price Volatility
A372320 volatility | |
---|---|
A372320 Average Weekly Movement | 7.5% |
Biotechs Industry Average Movement | 7.8% |
Market Average Movement | 5.0% |
10% most volatile stocks in KR Market | 11.4% |
10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A372320 has not had significant price volatility in the past 3 months.
Volatility Over Time: A372320's weekly volatility has decreased from 14% to 8% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | n/a | n/a | www.curocellbtx.com |
Curocell Inc. develops CAR-T cell therapy for the treatment of cancer. It focuses on the development of CD19 CAR-T for the treatment of lymphoma; and BCMA CAR-T for the treatment of multiple myeloma. The company was incorporated in 2016 and is based in Daejeon, South Korea.
Curocell Inc. Fundamentals Summary
A372320 fundamental statistics | |
---|---|
Market cap | ₩465.68b |
Earnings (TTM) | ₩0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A372320 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A372320 income statement (TTM) | |
---|---|
Revenue | ₩0 |
Cost of Revenue | ₩0 |
Gross Profit | ₩0 |
Other Expenses | ₩0 |
Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did A372320 perform over the long term?
See historical performance and comparison